Figure 2.

miR-29b inhibition ameliorates AngII-induced muscle atrophy in vivo

(A) Quantitative real-time PCR analysis of miR-29b expression when mice were treated with Fugw (control) and miR-29b sponge in AngII-induced muscle atrophy. n = 4, 4, 5, 5. (B) Gastrocnemius weight from control and AngII mice treated with Fugw or miR-29b sponge. n = 5, 6, 5, 6. (C) The grip strength of right hindlimb from control and AngII mice treated with Fugw or miR-29b sponge. n = 4, 4, 5, 4. (D) Quantitative real-time PCR analysis of Atrogin-1 and Murf-1 expression when control and AngII mice treated with Fugw or miR-29b sponge. n = 5–6 per group. (E) Wheat germ agglutinin (WGA) staining was performed to quantify muscle fiber cross-sectional area (CSA) from control and AngII mice treated with Fugw or miR-29b sponge. Scale bar: 20 μm. n = 5 per group. (F) TUNEL staining was performed to quantify apoptosis from control and AngII mice treated with Fugw or miR-29b sponge. Scale bar: 20 μm. n = 5, 5, 4, 5. (G) Western blot analysis for the ratio Bax/Bcl2, Cleaved-caspase 3/Caspase 3 when control and AngII mice treated with Fugw or miR-29b sponge. n = 3 per group. Data are shown as mean ± SD. ∗p < 0.05. ∗∗p < 0.01. See also Figure S2.